Caribou Biosciences, Inc., a Berkeley, California-based CRISPR genome-editing biopharmaceutical company, raised $304M in an initial public offering, one of the
Continue Reading Caribou Biosciences Raises $304M in Potentially the Largest Gene Editing IPO
On July 13, 2021, Prime Medicine, a Massachusetts biotech company developing next generation gene editing technology, emerged from stealth mode
Continue Reading Prime Medicine Emerges with $315 Million to Develop Next Generation Gene Editing Platform